Introduction: We have previously demonstrated that a subset of lung cancer cells express higher CYP24A1 mRNA, a metabolizing enzyme for 1,25-D3, compared to benign tumors or surrounding normal lung and that high CYP24A1 mRNA expression is associated with poor prognosis in resected lung adenocarcinoma (AC). We hypothesized that CYP24A1 has oncogenic potential and increased CYP24A1 expression may contribute to tumor growth, whereas, CYP24A1 targeting may reduce tumor burden.
Introduction
Cytochrome P450 family 24 subfamily A member 1 (CYP24A1) is a member of the cytochrome P450 superfamily of enzymes responsible for the metabolism of many drugs, steroids, and lipids. It is localized in the inner mitochondrial membrane as well as in the nucleus. Cytochrome P450 family 24 subfamily A member 1 gene (CYP24A1) encodes for 24-hydroxylase, the enzyme that catalyzes the inactivation of 1,25-dihydroxycholecalciferol (1,25-D 3 ) , the biologically active form of vitamin D. The vitamin D endocrine system plays an essential role in calcium homeostasis and bone metabolism, but research over two decades has revealed a diverse range of biological actions that include induction of cell differentiation and inhibition of cell growth. Under physiological conditions, bioactivation of 25-hydroxyvitamin D 3 to 1,25-D(3) occurs mainly in the kidney 1 ; other cell types can contribute to production of 1,25-D 3 in conditions such as sarcoidosis (alveolar epithelial cells) 2 and pregnancy. 3 However, the extrarenally produced 1,25-D 3 primarily serves as an autocrine/paracrine factor with cell-specific functions. 4 Most of the biological activities of 1,25-D 3 require a high-affinity receptor, the vitamin D receptor (VDR). The VDR acts as a ligand-activated transcription factor. 5 After ligand (1,25-D 3 ) binding, the VDR heterodimerizes with retinoid X receptor (RXR) and binds to vitamin D response elements in the promoter of 1,25-D 3 -responsive genes. The subsequent recruitment of VDR-interacting nuclear proteins (coregulators) into the transcriptional preinitiation complex enhances or suppresses the rate of gene transcription by the VDR. 5 The earliest gene that is activated (CYP24A1) is that encoding 24-hydroxylase; this gene contains a vitamin D response element in its promoter. CYP24A1 initiates the degradation of 1,25-D 3 by hydroxylation of the side chain to form inactive calcitroic acid. Basal extrarenal CYP24A1 expression is low and has been detected in a variety of vitamin D target tissues, including colon, small intestine, skin, heart, brain, testis, oocytes, and bone. 6 CYP24A1 expression is highly inducible by 1,25-D 3 in a VDR-retinoid X receptor-dependent manner 7 ; this induction by its substrate is part of an autocatalytic loop that in physiological states prevents toxicities from high 1,25-D 3 concentrations. Cell-autonomous control of vitamin D activity is tightly regulated by the action of the vitamin D-activating and vitamin D-inactivating hydroxylases CYP27B1 and CYP24A1, respectively. The resulting local concentrations of 1,25-D 3 lead to tissuespecific effects mediated directly by both 1,25-D 3 (genomic effects) and stimulation of cytokines and growth factors such as epidermal growth factor and transforming growth factor-b; the latter results in an autocrine/paracrine regulation by 1,25-D 3 that is associated with cell differentiation and proliferation.
Over the past decade, CYP24A1 has been shown to be highly expressed in numerous cancers, including esophageal, cervical, breast and colon cancers, as compared with in surrounding normal tissues. Mimori et al. 8 correlated overexpression of CYP24A1 and poor survival in esophageal cancer. We and others 9, 10 have reported upregulation of CYP24A1 in lung adenocarcinoma (AC).
Our initial studies revealed that at 5 years of follow-up after surgery for early-stage lung cancer, the probability of survival was 42% with a high CYP24A1 level versus 81% with a low CYP24A1 level. 9 The validation set of 101 lung ACs confirmed that CYP24A1 was independently prognostic of poor survival. 9 In parallel, we demonstrated that in vitro antiproliferative effects of 1,25-D 3 are inversely proportional to tumor CYP24A1 mRNA. Tumorspecific CYP24A1 is functional and able to catabolize 1,25-D 3. We and others 11 have demonstrated that increased expression in tumors may be related to different mechanisms and are not all mutually exclusive. For example, Albertson 11 reported that amplification and increase in gene copy number were associated with increased expression of CYP24A1. We found in lung cancer that a subset had focal amplification of this region on chromosome 20q13.2; however, epigenetic effects contributed to most lung cancers with increased CYP24A1 expression. Recent reports 12 have suggested that CYP24A1 has oncogenic effects in prostate and colon cancer. 13 In this article, we aimed to study the oncogenic properties of CYP24A1 in lung cancer.
Materials and Methods

Cell Lines and Chemicals
Human NSCLC lines SK-LU-1, H441, H1437, Calu-6, and A549 were obtained from the American Type Culture Collection (Manassas, Virginia). SK-LU-1, H441, and H1437 cells were grown in Roswell Park Memorial Institute-1640 medium, Calu-6 cells were grown in Eagle 0 s minimal essential medium, and A549 cells were grown in Dulbecco 0 s modified Eagle medium/nutrient mixture F12; in all cases, the medium was supplemented with 10% fetal bovine serum. All cells were maintained at 37 C with a 5% CO 2 -containing humidified incubator. Antibodies against anti-CYP24A1, anti-RAS, and anti-b actin were purchased from Abcam (Cambridge, MA), and anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Phospho-AKT (T308) and total-AKT antibodies were obtained from Cell Signaling Technology (Waltham, MA).
Stable Transfection of CYP24A1
CYP24A1 plasmid expressed in pLX304 vector was purchased from DNASU Plasmid Repository (Arizona State University Biodesign Institute, Tempe AZ) and the control vector (pLX304) was purchased from Addgene (Cambridge, MA). SK-LU-1 or Calu-6 cells were plated overnight in 12-well plates at a density of 50,000 cells per well to allow cells to adhere. The next day, plasmids were transfected into human lung cancer cell lines by using FuGENE 6 transfection reagent (Promega, Madison, WI) according to the manufacturer's protocol. Transfected cells were selected and maintained in culture medium containing blasticidin (10 mg/mL). Stable Transduction with shRNA Targeted to CYP24A1 pGIPZ lentivirus particles encoding either CYP24A1 or nontargeting (NT) short hairpin (shRNA) were purchased from Thermo Fisher Scientific and infected into high (A549) or moderate (H441) CYP24A1-expressing human lung cancer cell lines according to the manufacturer's instructions. Stably transduced cell lines were established by using puromycin selection. These cell lines were also transfected with luciferase-expressing vector for in vivo imaging studies to monitor tumor growth.
Extraction of RNA and RT-PCR
Total RNA was isolated from cell lines followed by column filtration using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA was eluted from the spin column with RNase-free water. Complementary DNA was prepared from RNA samples using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. Quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR) was performed using Power SYBR Green Master Mix (Thermo Fisher Scientific) with the ABI StepOne Real-Time PCR System. The primers used were as follows: CYP24A1 forward: 5 0 -GACATCCAGGCCACAGACAA-3 0 and CYP24A1 reverse: 5 0 -GATGGTGCTGACACAGGTGA-3 0 . b-actin was used to normalize CYP24A1 expression.
Cell Proliferation and Growth Assay
WST-1 cell proliferation reagent (Roche Life Science, Mannheim, Germany) was used to measure cell proliferation after knockdown of CYP24A1 in lung cancer cell lines. From 500 to 2000 cells per well were seeded in 96-well plates and cultured at 37 C for 3 to 6 days. At the end of the culture period, WST-1 reagent was added to each well and the absorbance was measured at wavelengths of 450 nm and 630 nm according to the manufacturer's instructions.
Growth of the population of cells transfected with CYP24A1 plasmid was tested by using a modified method of colorimetric crystal violet staining described previously. [14] [15] [16] Briefly, 5000 to 10,000 cells were seeded in a 12-well tissue culture plate and cultured for up to 13 days. At the end of the culture period, cells were washed twice with phosphate-buffered saline, fixed with methanol for 10 minutes at room temperature, and left to air dry. For a standard, variable numbers of cells (5,000 to 300,000 cells per well) were seeded in 12-well plates. Cells were stained with 0.5% crystal violet (wt/vol) for 10 minutes at room temperature. After removal of the excess dye, the cells were washed twice with distilled water. Dye was extracted in 30% acetic acid (vol/vol), optical density was measured at 595 nm, and cell numbers were calculated for each culture. Growth index was calculated by determining cell numbers at the time of harvest divided by cell numbers at time 0.
Clonogenic Cell Survival Assay
Clonogenic cell survival assays were performed to measure the fraction of surviving cells maintaining clonogenic ability after transfection with siRNA. Forty-eight hours after siRNA transfection, cells were trypsinized and plated at a clonal density in triplicate. After incubation for 10 to 14 days, the colonies formed were fixed with methanol and stained with 0.5% crystal violet. Only colonies consisting of more than 50 cells were counted. The fraction of cell colonies surviving after CYP24A1 knockdown was normalized to the survival of control siRNA-transfected cells.
Western Blotting
Cell lysates were prepared using cell lysis buffer (Cell Signaling Technology) according to the manufacturer's protocol. Protein concentrations in cell lysates were measured by using the bicinchoninic acid protein assay reagent (Pierce, Rockford, IL). Equal amounts of protein per sample was resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions and then transferred to a nitrocellulose membrane. After being blocked with 5% bovine serum albumin in Tris-buffered saline with 0.1% Tween 20, the membranes were incubated with different antibodies overnight at 4 C, washed three times with 0.1% Tween 20-Tris-buffered saline and then incubated for 60 minutes with 1:4000 peroxidaseconjugated anti-rabbit immunoglobulin G or anti-mouse immunoglobulin G. The membrane-bound peroxidase activity was detected by using ECL Prime Western Blotting Detection kits (Amersham, Arlington Heights, IL). Image J 1.32j software (National Institutes of Health, Bethesda, MD) was used to quantify band intensity.
Transwell Invasion Assay
Cancer cell invasion of CYP24A1-stably transfected cells was measured using the Boyden chamber (8-mm pore size [BD Biosciences, San Jose, CA]). Matrigel was obtained from BD Biosciences. Cells were cultured in the insert in a 24-well plate for 24 hours at 37 C. Inserts were coated with matrigel for the invasion assay. After 24 hours in culture, cells were fixed and stained with methylene blue and invading cells were counted.
Xenograft Models
NOD/SCIDg (NSG) mice were received from the Unit for Laboratory Animal Medicine at 6 to 8 weeks of age. All procedures were approved by the University Committee on Use and Care of Animals, and all animals received humane care in compliance with the Guide for the Care and Use of Laboratory Animals. To evaluate whether stable transfection of CYP24A1 shRNA modulates the tumorogenicity of A549 and H441, the number of cells injected was titrated to the lowest number resulting in a palpable tumor after flank injection of A549 cells stably transduced with NTshRNA or shCYP24A1 and H441 cells stably transduced with NT shRNA or shCYP24A1, respectively. Cells were passed through a 40-mm filter. Single-cell suspensions were prepared with 100 mL of saline and 50% Matrigel. Next, 2.5 Â 10 4 , 5 Â 10 4 , 1 Â 10 6 , and 2 Â 10 6 cells were injected into the flanks of NSG mice. Tumors were measured once a week, and tumor volumes were calculated on the basis of tumor width (W) and length (L) (W 2 L/2, where W < L). Each experimental group consisted of five mice injected with 1 Â 10 6 cells in each flank, for a total of 10 sites for each cell line. Mice were humanely killed when tumor size reached the maximum allowed limit of 1.5 Â 1.5 cm.
In Vivo Bioluminescent Imaging
Mice carrying tumors were injected with 150 mg/kg Firefly d-luciferin (Gold Biotechnology, St. Louis, MO) intraperitoneally. Fifteen minutes after luciferin injection, the mice were anesthetized in a plastic chamber filled with 2% isoflurane-air mixture and placed on a warmed stage, after which imaging was performed for 10 seconds to 5 minutes, depending on the tumor model and time point by using the Xenogen IVIS 100 Bioluminescent Imaging System (Perkin Elmer, Boston, MA). Bioluminescent imaging was performed weekly after tumor cell (A549 or H441) injection, depending on the tumor size. The excitation wave length (465 nm) and emission wave length (520 nm) were used to obtain bioluminescent images. The bioluminescent signal was measured in photons per second and quantified using Living Image software (Caliper Life Sciences, Alameda, CA).
Treatment of Cells with 1,25-D 3
For this study SK-LU-1 cells stably expressing CYP24A1 or HEK293 cells transiently transfected with either parental pLX304 vector or CYP24A1-expressing vector were plated as monolayers (400,000 cells per 60-mm dish). Twenty-four hours after plating/transfection, the respective cells were treated in the absence or presence of calcitriol (1,25-D 3 ) at a concentration of either 10 or 100 nM, and 24 hours after treatment, the cell lysates were subjected to immunoblotting.
Determination of Mitochondrial DNA Content
Mitochondrial DNA content was determined as described previously with modifications. Briefly, total genomic DNA was isolated using DNeasy blood and tissue kit (Qiagen) according to manufacturer's instructions. Mitochondrial DNA content was quantified 
Statistical Analysis
Analysis of variance (ANOVA) models were used to compare the (log-transformed) cell growth data between experimental groups. The model includes an interaction between group and time to test the group difference at each observed time point followed by the Tukey's test for multiple comparisons. The normality assumption was visually checked on the basis of various residual plots, and the Satterthwaite method was used to adjust the degrees of freedom for the unequal variances. Repeated measures ANOVA models were used to compare (log-transformed) tumor volumes between experimental groups. Unlike in the ANOVA model in the cell growth studies, a random effect was included in the model to consider the correlation between data measured within the same animal. In cell line studies for invasiveness, Wilcoxon rank sum tests were used with the Dwass-Steel-Chritchlow-Fligner method for multiple comparisons. Significance was defined as a p value less than 0.05. All analyses were conducted using SAS software, version 9.4 (SAS Institute, Inc., Cary, NC).
Results
CYP24A1 Overexpression Increases Cell Proliferation and Invasion in Lung Cancer Cells
To examine the oncogenic characteristics of CYP24A1, we selected five lung AC cell lines on the basis of the variability of CYP24A1 expression as quantified by RNA sequencing (Fig. 1A) . For the initial study, two low-CYP24A1-expressing human lung cancer cell lines, SK-LU-1 and Calu-6, were stably transfected with CYP24A1 expression vector. Increased CYP24A1 protein expression was confirmed in SK-LU-1 cells (Fig. 1B) and Calu-6 cells (Fig. 1D) transfected with CYP24A1 compared with in cells transfected with control vector pLX304 by immunoblotting. Growth curves of SK-LU-1 cells (Fig. 1C) or Calu-6 cells (Fig. 1E ), which were stably transfected with CYP24A1 or control vector (pLX304), were determined by crystal violet cell growth assay. 15, 16 The cell growth index of CYP24A1-overexpressing SK-LU-1 cells (5.05 ± 0.04) and Calu-6 cells (2.91 ± 0.05) was significantly higher than that of control vector pLX304-transfected SK-LU cells (4.37 ± 0.06) (p < 0.001) (Fig. 1C) and Calu-6 cells (1.42 ± 0.03) (p < 0.05) (Fig. 1E) .
Next, we asked whether CYP24A1 overexpression changes cell invasion capabilities. SK-LU-1 cells transfected with CYP24A1, empty vector, or parental cells were cultured in transwell inserts with Matrigel coating. Invading cell number was significantly higher in CYP24A1-overexpressing SK-LU-1 cells than in cells that were transfected with the control vector (490.8 ± 6.1 versus 46.6 ± 16.0, p < 0.05) (Fig. 1F and G) . These data suggest that CYP24A1 overexpression causes increased cell growth and invasion. Similar observations were obtained in Calu-6 cells overexpressing CYP24A1 (Fig. 1H  and I ).
CYP24A1 Knockdown by siRNA Decreased Lung Cancer Cell Survival
The effect of knockdown of CYP24A1 mRNA on lung cancer cell growth was tested. A549, a high-CYP24A1-expressing lung cancer cell line (Fig. 1A) , was transfected with siRNA against either CYP24A1 or NT sequence. Transfection with siRNA targeting CYP24A1 reduced CYP24A1 protein ( Fig. 2A) and CYP24A1 mRNA expression (93.8 ± 3.6%, p < 0.05) ( Supplementary  Fig. 1A ). Consequently, cell survival, assessed by WST-1 cell proliferation assay (54 0 ± 7.9%, p < 0.05), was reduced upon CYP24A1 knockdown (Fig. 2B) . Additionally, siRNA-mediated CYP24A1 knockdown caused loss of mitochondrial DNA content, as evidenced by reduced quantification of mitochondrial D-loop (0.54 ± 0.02) and cytochrome b (0.45 ± 0.11) DNA content by quantitative RT-PCR ( Fig. 2C and D) . The impact on nuclear DNA content upon CYP24A1 loss was marginal (0.75 ± 0.01). Next, cell lines moderately expressing CYP24A1, H441 and H1437, were used to further examine the effects of CYP24A1 knockdown on cell survival. CYP24A1 mRNA (Supplementary Fig. 1B ) and protein expression were reduced after transfection with siRNA targeting CYP24A1 (Fig. 2E ). In comparison with the case of NT siRNA, only 25.9 ± 3.7% (in the case of H441) (p < 0.05) and 59.2 ± 15.3% (in the case of H1437) (p < 0.05) CYP24A1 siRNA-transfected cells were able to form colonies (Fig. 2F ).
Stable Knockdown of CYP24A1 Reduces Tumor Growth in Mouse Xenograft Models
Stable knockdown of CYP24A1 in the cancer cell lines was achieved by infecting cells with lentiviral particles encoding CYP24A1 shRNA. Lentivirus-transduced cells expressing either CYP24A1 shRNA or NT shRNA were selected by culturing in media containing puromycin. Stable transduction with shRNA to CYP24A1 reduced CYP24A1 protein and mRNA expression in A549 cells compared with in cells transduced with NT shRNA (Fig. 3A and Supplementary Fig. 1C ). Cell survival, measured by clonogenic assay, showed reduction (61.1 ± 3.1, p ¼ 0.0004) in CYP24A1 shRNA-transduced cells compared with the NT control (p ¼ 0.0004) (Fig. 3B) . Similar results were obtained by using WST-1 assay (27.05 ± 3.32%) in shCYP24A1 transduced cells compared with shNT (p < 0.001) (data not shown). Various numbers of NT or CYP24A1 shRNA-infected cells were then injected into the flanks of NSG mice, and 2 weeks after implantation imaging of the mice was performed. As shown in Supplementary Figure 2A and quantified in Figure 3C , approximately 50-to 100-fold differences in bioluminescent intensity were observed between NT and CYP24A1 shRNA-transduced cells. Similarly, in the subsequent experiment in which we injected 1 Â 10 6 A549 cells into the flanks of NSG mice and measured tumor volumes on a regular basis, within 1 week after tumor detection, tumor volumes in the mice injected with A549 with CYP24A1 shRNA (5.77 ± 1.09 mm 3 ) were significantly smaller than in the mice injected with A549 with NT shRNA (46.11 ± 4.65 mm 3 ) (p < 0.05). This difference was even more pronounced at 4 weeks, with a fivefold difference in tumor volume between the two groups ( Supplementary Figs. 2B  and 3D ). Plotting of the average bioluminescence quantification also supported a similar trend when imaging was performed at 4 weeks after tumor detection but before tumor harvest (Fig. 3E) . To understand the impact of CYP24A1 knockdown on tumor cell proliferation, tumor sections from both NT and CYP24A1 shRNA-transduced samples were subjected to immunohistochemistry. As shown in Figure 3F , reduced Ki67 and cyclin D staining were noted in CYP24A1 shRNA-transduced A549 tumor cells. The lung cancer cell line H441 (with moderate expression of CYP24A1 mRNA) was used as the second cell line for xenograft experiments to confirm the effects of CYP24A1 knockdown on in vivo tumor growth. Similar to A549, shCYP24A1 reduced CYP24A1 protein and mRNA expression in H441 cells (Fig. 4A and Supplementary Fig. 1D ), which resulted in reduced (60.7 ± 7.8%) clonogenic survival (Fig. 4B) . Various numbers of such transduced cells (starting at 1.25 Â 10 5 to 2 Â 10 6 cells) were injected into the flanks of NSG mice, and imaging was performed 10 days after the injection; bioluminescence was detected in mice carrying 5 Â 10 5 NT shRNA-transduced H441 cells, which was 12.3-fold higher than in tumors generated from CYP24A1 shRNA-transduced H441 cells ( Supplementary Fig. 2C and Fig. 4C ). Such differences were visible between the groups when injected with 1 Â 10 6 cells. In the subsequent tumor growth studies, we injected 1 Â 10 6 cells and tumor growth was monitored on a weekly basis. Three weeks after cell injection, the tumor volume of H441 with CYP24A1 shRNA (282.96 ± 58.85 mm 3 ) was significantly less than that of H441 with NT shRNA (1265.43 ± 678.57 mm 3 ) (p < 0.05) (Fig. 4C) . Importantly, when the tumors were imaged for bioluminescence at the time of harvest, we noted an average 60% reduction in photonic flux in tumors carrying CYP24A1 shRNA-transduced H441 cells compared with in tumors with NT shRNA (Fig. 4D) . Additionally, similar to A549 cells in this model, shRNAmediated CYP24A1 knockdown also reduced Ki67 and cyclin D staining (Fig. 4E) , indicating an impact on H441 tumor cell proliferation. Together, we concluded that stable knockdown of CYP24A1 can reduce tumor growth in mouse xenograft models by affecting cell proliferation.
Complex Relationship between CYP24A1 and KRAS in NSCLC
The human lung cancer cell lines SK-LU-1 and Calu-6, which stably overexpressed CYP24A1, showed higher RAS protein expression compared with the cells transfected with the control vector pLX304 (Fig. 5A) .
Conversely, siRNA-mediated knockdown of CYP24A1 decreased RAS steady-state levels (Fig. 5B) . Such changes were also correlated with decreased AKT activation (Fig. 5B) , with minimal change in ERK activation (data not shown). Importantly, as mutant KRAS-driven lung cancer cells are known for their aggressive and highly proliferative behavior, we also analyzed CYP24A1 expression data in resected lung AC from The Cancer Genome Atlas 17 and measured CYP24A1 mRNA expression in 76 human lung cancer cell lines carrying either wild-type or mutant KRAS allele. 18 As predicted, patient tumors and cell lines showed significantly higher CYP24A1 mRNA in the presence of KRAS mutation ( Supplementary Fig. 3A and B) . Zhang et al. similarly noted a significant association between high CYP24A1 and KRAS mutation status in 147 lung cancer cases. 19 In contrast, data obtained from a large cohort of patients with NSCLC (n ¼ 230, p ¼ 0.012, log OR -1.647) showed mutual exclusivity between the presence of KRAS mutation and CYP24A1 gene amplification (database available from cBioportal) (Fig. 5C ). Taken together, here we identified a complex genetic linkage between CYP24A1 expression and KRAS mutation status and further found direct involvement of CYP24A1 in regulating tumor cell proliferation to promote oncogenesis, targeting of which may provide an alternate strategy to develop an anticancer response.
Discussion
We have previously reported that increased CYP24A1 mRNA expression is an independent poor prognostic factor for survival in lung AC. 9, 10 Others have similarly reported that increased CYP24A1 is a negative prognosticator of survival in esophageal, colon, breast, and ovarian cancer. 8, 20 The current study, in which both colorimetric and clonogenic in vitro assays were used, provides evidence that CYP24A1 has oncogenic properties, as overexpression leads to an increase in lung cancer cell growth. Overexpression of CYP24A1 also led to an increase in the invasive capabilities of lung cancer cells. Moreover, suppression of CYP24A1 gene expression led to decreased proliferation and growth in lung cancer cells in vitro, as well as in xenograft-bearing mouse models. These findings are similar to observations reported in prostate and colon cancer. 12, 13 Our data also reveal an independent effect of CYP24A1 on proliferation induced by RAS signaling. Overexpression of CYP24A1 led to accumulation of RAS proteins in two cell lines. Transfection with CYP24A1 siRNA decreased total RAS protein and reduced phosphorylated AKT levels, leading to decreased proliferation as evidenced by a reduction in Ki67 as well as in cyclin D1 immunoreactivity. It appears that there is a complex interrelationship between CYP24A1 and KRAS. KRAS-mutant lung ACs have been shown to exhibit increased CYP24A1 expression. Zhang et al. showed that K-ras mutation was associated with a median 4.2-fold increase in CYP24A1 mRNA expression. 19 Similarly, others have shown that CYP24A1 is preferentially expressed to a greater degree in thyroid cancers with other somatic oncogenic mutations. 21 These data , and cell lysates were prepared 48 hours after transfection and subjected to immunoblotting using the indicated antibodies. Band intensity was measured using Image J software and considering control sample as 1 (arbitrary units). (C) Tumor samples with sequencing data isolated from 230 patients with NSCLC were analyzed for KRAS mutation and cytochrome P450 family 24 subfamily A member 1 gene (CYP24A1) amplification (database available from http://www.cbioportal.org). A mutual exclusivity was noted between the two (log OR -1.647, p < 0.01). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
suggest that CYP24A1 overexpression is an adaptation to promote proliferation in KRAS-mutant cancer cells. The increase in CYP24A1 in these cancers may be epigenetic, as we have previously described 22 or it may be due to an increase in copy number as reported by Hobaus et al. 13 On the other hand, when we reviewed published data on cBioportal, we found to our surprise a small, yet distinct subset of lung ACs that exhibited focal amplification of the CYP24A1 gene (in 8% of cases); in these cases, presence of CYP24A1 amplification was mutually exclusive of KRAS mutations, suggesting that lung ACs with focal amplification of CYP24A1 may indeed form a distinct subset of lung ACs that can be targeted with specific CYP24A1 inhibitors.
We found that in addition to its effects on RAS signaling, siRNA-mediated knockdown of CYP24A1 reduced mitochondrial DNA content. It is known from previous studies that mitochondrial division affects mitosis progression 23 and the molecular regulators involved in such regulatory processes are starting to emerge. Our findings of the reduction of mitochondrial DNA content upon loss of CYP24A1 transcript are intriguing, and future studies may help us decipher a unique and direct role of CYP24A1 in tumor cell proliferation. Additionally, mitochondrial DNA content has been positively correlated with risk for various cancer risks, including lung and bladder cancers. 24, 25 So far among various molecular regulators, RAS-p66 Shc -mediated signaling has been linked to mitochondrial DNA replication 26 and proper mitochondrial division reported to be a requisite for the mutant RAS protein (KRAS G12D )-mediated transformation. 27 Thus, our findings on the linkage between RAS and CYP24A1 and an impact on mitochondrial DNA content are unique, and future studies will improve our molecular understanding of this process.
Taken together, our studies point to a direct effect of CYP24A1 on proliferation of lung AC. Increased expression of this rate-limiting catabolic enzyme is thought to restrict in situ 1,25-D 3 antiproliferative and growth-inhibitory activity, presumably by decreasing local levels of 1,25-D 3 . Attempts to provide exogenous 1,25-D 3 have not resulted in meaningful clinical benefit. This may be related to upregulation of CYP24A1 by 1,25-D 3 . It was previously reported and further confirmed here ( Supplementary Fig. 4 ) that 1,25-D 3 treatment leads to upregulation of CYP24A1. Interestingly, 1,25-D 3 , which is known to inhibit cell proliferation, increased CYP24A1 protein levels within 24 hours in human embryonic kidney (HEK293) and in SK-LU-1 cells overexpressing wild-type CYP24A1 ( Supplementary Fig. 4 ). This may be a partial explanation as to why our previous clinical trial using supraphysiological doses of 1,25-D 3 (200Â physiological doses) in patients with advanced NSCLC did not have a beneficial effect in all patients. 28 Variable levels of CYP24A1 in lung cancers may not lead to similar clinical responses in patients subjected to exogenous 1,25-D 3 . For individuals with high expression of CYP24A1, (particularly in those with focal amplification of the CYP24A1 gene), therapy with specific inhibitors of CYP24A1 may need to be considered to increase local tissue concentrations of 1,25-D 3 . In patients with lower expression of tumoral CYP24A1, exogenous high doses of 1,25-D 3 may shift the reaction to the right, but this effect would be limited by upregulation of CYP24A1 by 1,25-D 3 ; lower doses of CYP24A1 inhibitors may be necessary to increase endogenous substrate 1,25-D 3 levels in these patients.
In summary, in in vitro and in vivo models, we have established the oncogenic potential of CYP24A1, overexpression of which is correlated with a cancer cell's proliferative potential. We have also identified a genetic mutual exclusivity between CYP24A1-amplified lung AC and KRAS-mutant lung ACs in a small subset of lung ACs that may be targeted with CYP24A1 inhibitors. We speculate that CYP24A1 overexpression in itself may affect cell growth also in a 1,25-D 3 -independent manner. Further studies that tease out the catalytic activity of this enzyme versus independent growth-promoting aspects will need to be undertaken in a rigorous fashion, using site-directed mutagenesis of the various domains and determining the effects of such on cell cycle-related end points.
